Davinder Dhillon, APRN
Family · Wauconda, ILNPI 1780331033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $236 and has fallen 64.7% since, to $83 in 2025.
Across 22 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$108
- Phadia US Inc.$55
- Novo Nordisk$47
- Biohaven Pharmaceutical Holding Company Ltd.$44
- GSK$34
- Amgen$30
- plus $161 from 8 others
What the payments were for
- Food & beverage$479100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 4 | $108 |
| Phadia US Inc. | 1 | $55 |
| Novo Nordisk | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| GSK | 2 | $34 |
| Amgen | 2 | $30 |
| Lilly USA, LLC | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Cipher Pharmaceuticals US LLC | 1 | $22 |
| Medtronic | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Roche Diabetes Care, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$479 in reported general payments places this provider in the 60th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Permethrin | 33 | $1,807 |
| Warfarin Sodium | 53 | $442 |
| Levothyroxine Sodium | 23 | $181 |
| Metoprolol Tartrate | 16 | $158 |
| Metoprolol Succinate | 11 | $145 |
| Lisinopril | 22 | $128 |
| Triamcinolone Acetonide | 14 | $118 |
| Gabapentin | 11 | $116 |
| Duloxetine Hcl | 11 | $97 |
| Atorvastatin Calcium | 19 | $94 |
| Omeprazole | 11 | $86 |
| Metformin Hcl | 20 | $69 |
| Azithromycin | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Other family in Wauconda
- Ruth CarricoChicago$578K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Amy BrownellElk Grove Village$202K
- Brittony CroasdellChicago$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.